Access to oral osteoporosis drugs among female medicare part d beneficiaries

Chia Wei Lin, Pinar Karaca-Mandic, Jeffrey S. McCullough, Lesley Weaver

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: For women living with osteoporosis, high out-of-pocket (OOP) drug costs may prevent drug therapy initiation. We investigate the association between oral osteoporosis OOP medication costs and female Medicare beneficiaries' initiation of osteoporosis drug therapy. Methods: We used 2007 and 2008 administrative claims and enrollment data for a 5% random sample of Medicare beneficiaries. Our study sample included age-qualified, female beneficiaries who had no prior history of osteoporosis but were diagnosed with osteoporosis in 2007 or 2008. Additionally, we only included beneficiaries continuously enrolled in stand-alone prescription drug plans. We excluded beneficiaries who had a chronic condition that was contraindicated with osteoporosis drug utilization. Our final sample included 25,069 beneficiaries. Logistic regression analysis was used to examine the association between the OOP costs and initiation of oral osteoporosis drug therapy during the year of diagnosis. Findings: Twenty-six percent of female Medicare beneficiaries newly diagnosed with osteoporosis initiated oral osteoporosis drug therapy. Beneficiaries' OOP costs were not associated with the initiation of drug therapy for osteoporosis. However, there were significant racial disparities in beneficiaries' initiation of drug therapy. African Americans were 3 percentage points less likely to initiate drug therapy than Whites. In contrast, Asian/Pacific Islander and Hispanic beneficiaries were 8 and 18 percentage points, respectively, more likely to initiate drug therapy than Whites. Additionally, institutionalized beneficiaries were 11 percentage points less likely to initiate drug therapy than other beneficiaries. Conclusions: Access barriers for drug therapy initiation may be driven by factors other than patients' OOP costs. These results suggest that improved osteoporosis treatment requires a more comprehensive approach that goes beyond payment policies.

Original languageEnglish (US)
JournalWomen's Health Issues
Volume24
Issue number4
DOIs
StatePublished - Jan 1 2014

Fingerprint

bone disease
Medicare
Osteoporosis
drug
Drug Therapy
Pharmaceutical Preparations
Health Expenditures
costs
medication
Drug Utilization
Drug Costs
Prescription Drugs
Hispanic Americans
African Americans
random sample
Logistic Models
Regression Analysis
regression analysis

Cite this

Access to oral osteoporosis drugs among female medicare part d beneficiaries. / Lin, Chia Wei; Karaca-Mandic, Pinar; McCullough, Jeffrey S.; Weaver, Lesley.

In: Women's Health Issues, Vol. 24, No. 4, 01.01.2014.

Research output: Contribution to journalArticle

Lin, Chia Wei ; Karaca-Mandic, Pinar ; McCullough, Jeffrey S. ; Weaver, Lesley. / Access to oral osteoporosis drugs among female medicare part d beneficiaries. In: Women's Health Issues. 2014 ; Vol. 24, No. 4.
@article{491014d4c479484d9fe5cf6f4878f5b0,
title = "Access to oral osteoporosis drugs among female medicare part d beneficiaries",
abstract = "Background: For women living with osteoporosis, high out-of-pocket (OOP) drug costs may prevent drug therapy initiation. We investigate the association between oral osteoporosis OOP medication costs and female Medicare beneficiaries' initiation of osteoporosis drug therapy. Methods: We used 2007 and 2008 administrative claims and enrollment data for a 5{\%} random sample of Medicare beneficiaries. Our study sample included age-qualified, female beneficiaries who had no prior history of osteoporosis but were diagnosed with osteoporosis in 2007 or 2008. Additionally, we only included beneficiaries continuously enrolled in stand-alone prescription drug plans. We excluded beneficiaries who had a chronic condition that was contraindicated with osteoporosis drug utilization. Our final sample included 25,069 beneficiaries. Logistic regression analysis was used to examine the association between the OOP costs and initiation of oral osteoporosis drug therapy during the year of diagnosis. Findings: Twenty-six percent of female Medicare beneficiaries newly diagnosed with osteoporosis initiated oral osteoporosis drug therapy. Beneficiaries' OOP costs were not associated with the initiation of drug therapy for osteoporosis. However, there were significant racial disparities in beneficiaries' initiation of drug therapy. African Americans were 3 percentage points less likely to initiate drug therapy than Whites. In contrast, Asian/Pacific Islander and Hispanic beneficiaries were 8 and 18 percentage points, respectively, more likely to initiate drug therapy than Whites. Additionally, institutionalized beneficiaries were 11 percentage points less likely to initiate drug therapy than other beneficiaries. Conclusions: Access barriers for drug therapy initiation may be driven by factors other than patients' OOP costs. These results suggest that improved osteoporosis treatment requires a more comprehensive approach that goes beyond payment policies.",
author = "Lin, {Chia Wei} and Pinar Karaca-Mandic and McCullough, {Jeffrey S.} and Lesley Weaver",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.whi.2014.04.002",
language = "English (US)",
volume = "24",
journal = "Women's Health Issues",
issn = "1049-3867",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Access to oral osteoporosis drugs among female medicare part d beneficiaries

AU - Lin, Chia Wei

AU - Karaca-Mandic, Pinar

AU - McCullough, Jeffrey S.

AU - Weaver, Lesley

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: For women living with osteoporosis, high out-of-pocket (OOP) drug costs may prevent drug therapy initiation. We investigate the association between oral osteoporosis OOP medication costs and female Medicare beneficiaries' initiation of osteoporosis drug therapy. Methods: We used 2007 and 2008 administrative claims and enrollment data for a 5% random sample of Medicare beneficiaries. Our study sample included age-qualified, female beneficiaries who had no prior history of osteoporosis but were diagnosed with osteoporosis in 2007 or 2008. Additionally, we only included beneficiaries continuously enrolled in stand-alone prescription drug plans. We excluded beneficiaries who had a chronic condition that was contraindicated with osteoporosis drug utilization. Our final sample included 25,069 beneficiaries. Logistic regression analysis was used to examine the association between the OOP costs and initiation of oral osteoporosis drug therapy during the year of diagnosis. Findings: Twenty-six percent of female Medicare beneficiaries newly diagnosed with osteoporosis initiated oral osteoporosis drug therapy. Beneficiaries' OOP costs were not associated with the initiation of drug therapy for osteoporosis. However, there were significant racial disparities in beneficiaries' initiation of drug therapy. African Americans were 3 percentage points less likely to initiate drug therapy than Whites. In contrast, Asian/Pacific Islander and Hispanic beneficiaries were 8 and 18 percentage points, respectively, more likely to initiate drug therapy than Whites. Additionally, institutionalized beneficiaries were 11 percentage points less likely to initiate drug therapy than other beneficiaries. Conclusions: Access barriers for drug therapy initiation may be driven by factors other than patients' OOP costs. These results suggest that improved osteoporosis treatment requires a more comprehensive approach that goes beyond payment policies.

AB - Background: For women living with osteoporosis, high out-of-pocket (OOP) drug costs may prevent drug therapy initiation. We investigate the association between oral osteoporosis OOP medication costs and female Medicare beneficiaries' initiation of osteoporosis drug therapy. Methods: We used 2007 and 2008 administrative claims and enrollment data for a 5% random sample of Medicare beneficiaries. Our study sample included age-qualified, female beneficiaries who had no prior history of osteoporosis but were diagnosed with osteoporosis in 2007 or 2008. Additionally, we only included beneficiaries continuously enrolled in stand-alone prescription drug plans. We excluded beneficiaries who had a chronic condition that was contraindicated with osteoporosis drug utilization. Our final sample included 25,069 beneficiaries. Logistic regression analysis was used to examine the association between the OOP costs and initiation of oral osteoporosis drug therapy during the year of diagnosis. Findings: Twenty-six percent of female Medicare beneficiaries newly diagnosed with osteoporosis initiated oral osteoporosis drug therapy. Beneficiaries' OOP costs were not associated with the initiation of drug therapy for osteoporosis. However, there were significant racial disparities in beneficiaries' initiation of drug therapy. African Americans were 3 percentage points less likely to initiate drug therapy than Whites. In contrast, Asian/Pacific Islander and Hispanic beneficiaries were 8 and 18 percentage points, respectively, more likely to initiate drug therapy than Whites. Additionally, institutionalized beneficiaries were 11 percentage points less likely to initiate drug therapy than other beneficiaries. Conclusions: Access barriers for drug therapy initiation may be driven by factors other than patients' OOP costs. These results suggest that improved osteoporosis treatment requires a more comprehensive approach that goes beyond payment policies.

UR - http://www.scopus.com/inward/record.url?scp=84903465856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903465856&partnerID=8YFLogxK

U2 - 10.1016/j.whi.2014.04.002

DO - 10.1016/j.whi.2014.04.002

M3 - Article

C2 - 24837398

AN - SCOPUS:84903465856

VL - 24

JO - Women's Health Issues

JF - Women's Health Issues

SN - 1049-3867

IS - 4

ER -